FFRCT in Practice: Advancing CCTA Interpretation and Clinical Decision-Making
Description

Learner Objective

Upon completion of this activity, you should be able to:

  1. Describe the role of AI-enhanced tools using FFRCT analysis in complementing CCTA for improved diagnostic accuracy. 

Faculty

Ron Blankstein, MD, FACC  

Brigham and Women's Hospital  

Boston, MA  

Disclosures: 

Consultant Fees/Honoraria: Amgen Inc.; Caristo Diagnostics; Elucid; Heartflow; Nanox AI; Novartis, Siemens  

Research/Research Grants: Amgen Inc.; Nanox AI; Novartis Corporation  

 

Planning Committee

Monvadi Barbara Srichai-Parsia, MD, FACC  

Georgetown University Hospital  

Washington, D.C.

Disclosures:

Consultant Fees/Honoraria: Artrya; AstraZeneca Pharmaceuticals; Bioclinica; Update 

 

Carol M. Patrick, DNP  

Northwell Health  

Commack, NY

Disclosures:

Consultant Fees/Honoraria: PCNA (Preventative Cardiovascular Nurses Association); Pfizer/Bristol Myers Squibb 


Grant Acknowledgement
Educational grant support for this activity provided by: Heartflow

Summary
Availability:
On-Demand
Access expires on Oct 16, 2026
Cost:
FREE
Credit Offered:
0.75 CME Credit
0.75 CNE Credit
0.75 AAPA Credit
0.75 ABIM-MOC Point
0.75 IPCE Credit
Android App Download IOS App Download Powered By